Palatin Technologies Inc. (PTN) news stock charts
Palatin Technologies Inc. (PTN) Investment Summary:
Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company?s products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey.www.palatin.com
43 Employees
Founded in 1986
PALATIN TECHNOLOGIES INC (PTN:AMEX)
LAST $0.26 USD
CHANGE TODAY +0.001 0.38%
VOLUME 27.8K
As of 10:43 AM 03/16/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of PALATIN TECHNOLOGIES INC (PTN)
|
OPEN
$0.27
|
PREVIOUS CLOSE
$0.26
|
|
|
DAY HIGH
$0.27
|
DAY LOW
$0.26
|
|
|
52 WEEK HIGH
08/12/09 - $0.48
|
52 WEEK LOW
03/16/09 - $0.07
|
|
|
MARKET CAP
25.2M
|
AVERAGE VOLUME 10 D
469.0K
|
|
|
EPS TTM
$0.04
|
SHARES OUTSTANDING
96.7M
|
|
|
PTN Does Not Pay Dividends
|
P/E TTM
6.5x
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for PALATIN TECHNOLOGIES INC (PTN)
Palatin Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2009
02/16/2010
Palatin Technologies Inc. announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2009. The company reported net income of $4.5 million, or $0.04 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $0.4 million, or $0.00 per basic and diluted share, for the same period in 2008. Total revenues in the quarter ended December 31, 2009 were $7.3 million, compared to $1.2 million for the same period in 2008. The increase in net income for the quarter ended December 31, 2009, compared to the same period last fiscal year, was primarily due to an increase in revenue recognized under Palatin's license and clinical trial agreements with AstraZeneca AB (AstraZeneca). For the quarter, the company reported income from operations of $3,435,465, income before tax of $3,503,467 compared with loss from operations of $2,779,521, loss before tax of $2,158,841 for the same period a year ago. For the six months, the company reported income from operations of $3,274,789, income before tax of $3,466,402 and net income of $4,464,810 or $0.04 per diluted share on revenues of $10,945,918 compared with loss from operations of $7,140,522, loss before tax of $6,441,356 and net loss of $4,699,880 or $0.05 per diluted share on revenues of $1,965,251 for the same period a year ago.
Palatin Technologies Inc. expected to Report Q3 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on February 16, 2010).
02/16/2010
Palatin Technologies Inc. expected to Report Q3 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on February 16, 2010).
Palatin Technologies Inc., Q2 2010 Earnings Call, Feb-16-2010
02/16/2010
Palatin Technologies Inc., Q2 2010 Earnings Call, Feb-16-2010
Palatin Technologies Inc. financial resources
PTN Competitors
| Company | Last | Change | |
| No competitor information is available for PTN. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | PTN | Industry Range |
| Price/Earnings | 6.1x |
|
| Price/Sales | 1.2x |
|
| Price/Book | 2.2x |
|
| Price/Cash Flow | 5.8x |
|
| TEV/Sales | 0.9x |
|
|
PTN |
||
|
PTN transactions
| Type Date |
Target |
|
Private Placement
February 24, 2010 |
-- |
More Recent Financial News About Palatin Technologies Inc.
Palatin Technologies Earnings Call scheduled for 11:00 am ET today
2010-03-04 01:01:53
Quote: Call DetailsPalatin Technologies Earnings Conference Call (Q2 2010)Tue,
Feb 16, 2010, 11:00 am EasternAbout Palatin TechnologiesPTN)Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company’s products under development include PL-3994, a peptide mimetic natriuretic peptide recept...Read article
Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
2010-03-01 05:58:23
Quote: 25 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has entered into definitive agreements with certain accredited investors to sell in a registered direct offering 9.6 million units at a price of $0.27 per unit for gross proceeds of $2.6 million, before deducting placement agent fees and other offering expenses. Â Each unit will consist of (i) one share of common stock, (ii) a Series A warrant exercisable 181 days after issuance and expiring 3 year...Read article
Skymark Research Initiates Independent Research Coverage on Palatin Technologies, Inc.
2010-02-26 07:21:02
Quote: 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Palatin Technologies, Inc. (NYSE: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market...Read article
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
2010-02-25 06:37:43
Quote: 16 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its second quarter ended December 31, 2009. Â Palatin reported net income of $4.5 million, or $0.04 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $0.4 million, or $0.00 per basic and diluted share, for the same period in 2008. Â Total revenues in the quarter ended December 31, 2009 were $7.3 million, compared to $1.2 million for the same perio...Read article
Palatin Technologies Inc. Q4 2009 Earnings Call Transcript
2010-02-19 04:33:04
Quote: Palatin Technologies Inc. (PTN)
Q4 2009 Earnings Call
February 16, 2010 11:00 am ET
Executives
Carl Spana - President & CEO
Steven Wills - CFO & EVP, Operations
Trevor Hallam - EVP of Research & Development
Analysts
Matt Kaplan - Ladenburg
Presentation
Operator
Good morning ladies and gentlemen and welcome to the Palatin Technologies second quarter fiscal year 2010 conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-...Read article
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
2010-02-17 09:13:40
Quote: 16 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its second quarter ended December 31, 2009. Â Palatin reported net income of $4.5 million, or $0.04 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $0.4 million, or $0.00 per basic and diluted share, for the same period in 2008. Â Total revenues in the quarter ended December 31, 2009 were $7.3 million, compared to $1.2 million for the same perio...Read article
Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
2010-02-16 06:31:35
Quote: 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs."The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate."Our natriuretic compounds, including PL-3994, address significant unmet medical needs," said Trevor Ha...Read article
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
2010-02-16 06:31:34
Quote: 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. Â The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. Â The study will also evaluate consistency of plasma exposure of bremelanotide given as repea...Read article
Skymark Research Initiates Independent Research Coverage on Palatin Technologies, Inc.
2010-02-16 06:31:34
Quote: 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Palatin Technologies, Inc. (NYSE: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market...Read article
PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report
2010-02-16 06:31:33
Quote: Our future operating results are subject to risks
and uncertainties and are dependent upon many factors, including, without
limitation, the risks identified in this report, in our annual report on Form
10-K for the year ended June 30, 2009 and in our other Securities and Exchange
Commission (SEC) filings.
We expect to incur losses in the future as a result of spending on our planned
development programs and losses may fluctuate significantly from quarter to
quarter.
In this quarterly report on F...Read article
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
2010-02-09 08:20:52
Quote: 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. Â The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. Â The study will also evaluate consistency of plasma exposure of bremelanotide given as repea...Read article
Skymark Research Initiates Independent Research Coverage on Palatin Technologies, Inc.
2010-02-04 01:35:09
Quote: 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Palatin Technologies, Inc. (NYSE: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market...Read article
Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
2009-12-02 03:27:58
Quote: 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs."The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate."Our natriuretic compounds, including PL-3994, address significant unmet medical needs," said Trevor Ha...Read article
PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report
2009-11-30 04:06:17
Quote: Our future operating results are subject to risks
and uncertainties and are dependent upon many factors, including, without
limitation, the risks identified in this report, in our annual report on Form
10-K for the year ended June 30, 2009 and in our other Securities and Exchange
Commission (SEC) filings.
We expect to incur losses in the future as a result of spending on our
planned development programs and losses may fluctuate significantly from quarter
to quarter.
In this quarterly report on F...Read article
Palatin Technologies, Inc. To Report Fiscal Year 2010 First Quarter Results; Teleconference and Webcast to be held on November 16, 2009
2009-11-30 04:06:17
Quote: ETDomestic Dial-In Number1-888-801-6504International Dial-In Number1-913-312-4376Passcode8561334-- Q1 & Fiscal Year 2010 ConferenceCall-Replay11/16-11/23/2009Domestic Dial-In Number1-888-203-1112International Dial-In Number1-719-457-0820Passcode8561334-- Webcast Live and Replay AccessPalatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.Palatin's strategy is to develop products and t...Read article
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
2009-11-30 04:06:16
Quote: 16 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its quarter ended September 30, 2009.Palatin reported a net loss of $37,000, or $(0.00) per basic and diluted share, for the quarter ended September 30, 2009, compared to a net loss of $4.3 million, or $(0.05) per basic and diluted share, for the same period in 2008.Total revenues in the quarter ended September 30, 2009 were $3.7 million, compared to $754,000 for the same period in 2008.The decre...Read article
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
2009-11-30 04:06:15
Quote: Palatin Technologies (PTN)
F1Q10 Earnings Call
November 16, 2009 11:00 am ET
Executives
Carl Spana, Ph.D. - President and Chief Executive Officer
Stephen T. Wills - Chief Financial Officer
Trevor Hallam, Ph.D. - Executive Vice President of R&D
Analysts
Matt Kaplan – Ladenburg Thalmann
Presentation
Operator
Good morning, ladies and gentlemen, and welcome to Palatin Technologies’ first quarter fiscal year 2010 conference call. (Operator Instructions)
Before we begin our remarks...Read article
Palatin Technologies Earnings Call scheduled for 11:00 am ET today
2009-11-30 04:06:15
Quote: Call DetailsPalatin Technologies Earnings Conference Call (Q1 2010)Mon,
Nov 16, 2009, 11:00 am EasternAbout Palatin TechnologiesPTN)Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company’s products under development include PL-3994, a peptide mimetic natriuretic peptide recept...Read article
Would you like to leave a comment about Palatin Technologies Inc. PTN
Find out what social network information about Palatin Technologies Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Palatin Technologies Inc.'s Stock there is more great penny stock and market information at Realpennies